HI
MDGL icon

HBK Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

HBK Investments’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-75,000
Closed -$6.83M – 320
2019
Q4 		$6.83M Buy
+75,000
New +$7.27M 0.07% 193

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

HBK Investments's MDGL Position: Q1 2020 in Review

HBK Investments sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2020, closing a stake of 75,000 shares — an estimated $6.83M sold.

HBK Investments first reported a position in MDGL in Q4 2019 and held it in 1 quarter. The position peaked at $6.83M in Q4 2019. 109 funds tracked by Wall St. Rank hold MDGL as of Q1 2020.

  • HBK Investments reported no remaining Madrigal Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • HBK Investments sold 75,000 Madrigal Pharmaceuticals shares in Q1 2020, an estimated $6.83M.
  • HBK Investments first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • HBK Investments's Madrigal Pharmaceuticals position peaked at $6.83M in Q4 2019.
  • 109 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2020.

Based on HBK Investments's 13F filing for Q1 2020, filed 15 May 2020.